StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Monday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, January 14th.

Ekso Bionics Stock Performance

EKSO opened at $0.44 on Monday. The company has a market cap of $9.64 million, a PE ratio of -0.67 and a beta of 1.46. The stock has a 50-day moving average of $0.61 and a 200-day moving average of $0.82. Ekso Bionics has a 52-week low of $0.37 and a 52-week high of $1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. As a group, equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.